Extended report: A randomised double-blind phase III study comparing SB2 an infliximab biosimilar to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy

摘要

ObjectivesTo compare the efficacy, safety, immunogenicity and pharmacokinetics (PK) of SB2 to the infliximab reference product (INF) in patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate therapy.